ADCs in Development for the Treatment of Lung Cancer
Drs Martin Dietrich and Wade Thomas Iams discuss the differences between the targets, payloads, and linker technologies of the antibody drug conjugates in development for lung cancer.
Overview of Antibody Drug Conjugates in Lung Cancer
Wade Thomas Iams, MD, provides an overview of antibody drug conjugates in the treatment of patients with lung cancer, including challenges and impact on clinical practice.
Emerging Concepts on the Role of Immunotherapy in NSCLC
Martin Dietrich, MD, PhD, and Meghan J. Mooradian, MD, conclude their discussion by discussing how they address treatment toxicity in NSCLC.
Future Perspectives in Biomarker Testing and Targeted Therapy in NSCLC
Expert oncologists look to the future of the NSCLC treatment landscape and discuss unmet needs and promising therapies.
NSCLC: Discussing Molecular Biomarkers and Treatment Decisions with Patients
Meghan J. Mooradian, MD, shares her approach to communicating with patients with NSCLC regarding treatment decisions based on molecular biomarkers.
Immunotherapy in NSCLC With Concurrent KRAS/STK11 or KRAS/KEAP-1 Mutations
Takeaways from the CheckMate 9LA, CheckMate 227, and POSEIDON trials focused on immunotherapy in non–small cell lung cancer.
Treatment Approaches for NSCLC With Concurrent KRAS/STK11 or KRAS/KEAP-1 Mutations
Meghan J. Mooradian, MD, discusses how she makes NSCLC treatment decisions based on concurrent mutations.
Clinical Insights on the Role of PD-1/PD-L1 Inhibitors in NSCLC
Martin Dietrich, MD, PhD, describes his approach to using anti-PD-1 therapies in non–small cell lung cancer.
Applying Molecular Biomarkers in Treatment Decision Making in NSCLC
An overview of the prevalence of molecular biomarkers in NSCLC and their effect on treatment decisions.
Navigating Barriers to Molecular Testing and Role of Liquid Biopsy in NSCLC
Expert oncologists discuss barriers to molecular testing and the use of liquid biopsy in non–small cell lung cancer.
The Role of Molecular Testing In Metastatic NSCLC
Martin Dietrich, MD, PhD, and Meghan J. Mooradian, MD, give an overview of the role of molecular biomarkers in the non–small cell lung cancer treatment space.
KRAS G12C–Mutated NSCLC: Real-World Implications of Novel Targeted Therapy
Closing out their review of treatment options for KRAS G12C–mutated NSCLC, expert oncologists look toward future utilization of novel targeted agents in this setting.
2L KRAS Inhibitors for Patients With KRAS G12C–Mutated NSCLC
Centering discussion on KRAS inhibitors and associated clinical trials, Martin Dietrich, MD, PhD, and Joshua Sabari, MD, detail the second-line management of KRAS G12C–mutated non–small cell lung cancer.
Non–Small Cell Lung Cancer: Selecting 1L Therapy for Patients With KRAS G12C Mutations
Key opinion leaders identify the first-line treatment armamentarium for patients with KRAS G12C–mutated non–small cell lung cancer.
Non–Small Cell Lung Cancer: Informing 1L Therapy Selection With Molecular Testing
A brief review of how results from adequate molecular testing may help to inform the first-line management of non–small cell lung cancer.
Overcoming Barriers to Molecular Testing in Non–Small Cell Lung Cancer
A comprehensive discussion on how to overcome barriers that may inhibit access to adequate molecular testing in patients with non–small cell lung cancer.
Addressing Inadequate Molecular Testing in Patients With NSCLC
Expert perspectives on course-correcting the management of patients with NSCLC who may not have received adequate molecular profiling in the past.
Non–Small Cell Lung Cancer: Optimizing the Identification of KRAS G12C Mutations
Shared insight on best practices in non–small cell lung cancer management to utilize molecular testing and identify patients harboring KRAS G12C mutations.
Understanding the Nature of a KRAS G12C Mutation in NSCLC
Expert oncologists Martin Dietrich, MD, PhD, and Joshua Sabari, MD, elucidate the emergence of KRAS G12C as a molecular marker in the setting of non–small cell lung cancer.
Biomarker Testing Standards-of-Care in Breast and Lung Cancer
The panel shares their recommendations for biomarker testing standard-of-care in breast cancer and lung cancer.
Monitoring Patients on First-Line Treatment for Metastatic Breast Cancer
Ellen Ball, ANP-FNP, reviews how patients are monitored for treatment response and toxicities during first-line treatment.
Targeted Therapy in Metastatic Breast Cancer for Patients with BRCA Mutations
Key opinion leaders explain how early they introduce targeted therapy in mutated breast cancer.
Further Molecular Testing in Early-Stage Metastatic Breast Cancer
Gregory Vidal, MD, PhD, discusses the potential use of further molecular testing in early-stage first-line breast cancer.
Biomarker-Influenced Treatment Approaches for Patients with Metastatic Lung Cancer
Martin Dietrich, MD, PhD, explains the rationale for the chosen treatment approach in the presented clinical scenario of metastatic lung cancer.
Clinical Scenario: A 74-Year-Old Man with Lung Cancer
A panel of experts discusses the clinical scenario of a 74-year-old man with metastatic lung cancer and the best genetic testing approach.
Discussing Biomarker Testing with Patients
Ellen Ball, ANP-FNP, provides a look at the conversations she has with patients when discussing their options for genetic testing in breast cancer.
Use of Liquid Biopsies in Breast Cancer
Drs McKenzie and Vidal debate the use of liquid biopsies in breast cancer.
Challenges of Biomarker Testing in Breast Cancer
Dr Gregory Vidal describes the approaches for biomarker testing in breast cancer and the challenges clinicians face.
Biomarker Testing Interpretation in Breast and Lung Cancer
Andrew McKenzie, PhD, details how to interpret the results of biomarker testing in breast cancer and lung cancer.
Choosing a Molecular Testing Panel for Solid Tumors
Dr Andrew McKenzie explains how to choose the appropriate molecular testing for a patient.
Epcoritamab Plus Rituximab/Lenalidomide Produces Responses in High-risk R/R Follicular Lymphoma
TTFields Plus SOC Improves OS in Metastatic NSCLC After Progression on Platinum-based Chemotherapy
Liso-Cel Leads to Rapid Responses, High Undetectable MRD Rates in Relapsed/Refractory CLL/SLL
Datopotamab Deruxtecan Plus Pembrolizumab With or Without Chemo Produces Responses in Advanced NSCLC
2 Clarke Drive Cranbury, NJ 08512